Pharmaceutical Industry Reports cancer metabolism based therapeutics market | Page 2

REPORT DESCRIPTION
Cancer Metabolism Based Therapeutics Market – Overview
According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery
of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the
amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that
heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism
rate. Cancer metabolism is based on the principle of cancer cells, which alter the metabolism of glucose and
glutamine for the synthesis of lipids, nucleotides, fatty acids, and proteins that helps to proliferate cancer cells.
It results in inhibition of various metabolic pathways, such as the citric acid cycle, glucose, mitochondrial
respiration, and glutamine utilization. Limited options of cancer metabolism targeting therapies are expected
provide potential opportunities for development of novel cancer metabolism-based therapeutics in the near future.
Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound -
Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic
acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug
Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid
leukemia (AML), and Myelodysplastic syndromes (MDS).